UK Authority Recommends Eli Lilly's Famed Diabetes Drug Mounjaro As New Treatment Option For Type 2 Diabetes
Portfolio Pulse from Vandana Singh
UK's National Institute for Health and Care Excellence (NICE) has endorsed Eli Lilly's diabetes medication, Mounjaro, as a viable treatment for type 2 diabetes. This comes amid national shortages of Novo Nordisk's Ozempic, a similar drug. NICE estimates that around 180,000 individuals could benefit from Mounjaro. The drug has also shown potential in combating obesity. The final guidance from NICE is expected on October 11, after which Mounjaro will be available within the UK's National Health Service.
September 08, 2023 | 1:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's diabetes drug Mounjaro has been endorsed by UK's NICE as a viable treatment for type 2 diabetes. The drug also shows potential in combating obesity.
The endorsement by NICE could lead to increased sales of Mounjaro in the UK, especially given the current shortage of a similar drug, Ozempic. Additionally, the drug's potential in combating obesity could open up a new market for Eli Lilly.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Novo Nordisk's diabetes drug Ozempic is facing national shortages in the UK. This comes as UK's NICE endorses a similar drug, Mounjaro, by Eli Lilly.
The shortage of Ozempic in the UK could lead to a decrease in sales for Novo Nordisk. Furthermore, the endorsement of a similar drug, Mounjaro, by NICE could lead to a shift in market share.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 60